Clinical Trial News and Research

RSS

Phenoxodiol, an investigational drug shows promise for ovarian cancer

A new study further supports the unique mechanism of action of phenoxodiol, an investigational drug being studied for the treatment of ovarian cancer.

2 May 2007

Eli Lilly to publish grant and contribution information

Eli Lilly and Company has announced that it will begin posting online all educational grant funding and other monetary contributions provided to U.S.-based organizations.

2 May 2007

Revolutionary treatment for blindness

The first clinical trial to test a revolutionary treatment for blindness in children has been announced by researchers at UCL (University College London).

2 May 2007

Spherix starts phase 3 clinical trial of treatment for type 2 diabetes

Spherix Incorporated has announced that it has begun its Phase 3 clinical trial of Naturlose as a treatment for Type 2 diabetes.

2 May 2007

Testosterone cream does not increase sexual drive in female cancer survivors

Increasing the testosterone levels of female cancer survivors using testosterone cream did not improve their libido more than a placebo, according to a randomized controlled clinical trial in the May 2 Journal of the National Cancer Institute.

2 May 2007

Drg resistant HIV quickly hides in infants' cells

New evidence shows that drug-resistant virus passed from mother-to-child can quickly establish itself in infants, CD4+ T cells where it can hide for years, likely limiting their options for future treatment.

1 May 2007

FDA approves INVEGA treatment for schizophrenia

The U.S. Food and Drug Administration (FDA) has approved INVEGA (paliperidone) Extended-Release Tablets, a new once-daily, atypical antipsychotic, for the long-term maintenance treatment of schizophrenia.

30 Apr 2007

Potential new treatment for desmoid fibromatosis

New hope is available for children who have a tumor called desmoid fibromatosis, according to results of a national clinical trial that was led by a St. Jude researcher.

27 Apr 2007

Sangamo BioSciences starts phase 2 trial of therapy diabetic neuropathy

Sangamo BioSciences has announced that the company has initiated a repeat-dosing, multi-center Phase 2 clinical trial of SB-509 in subjects with moderate to severe diabetic peripheral sensory motor neuropathy (DN).

27 Apr 2007

Novagali Pharma announces FDA clearance of trial for treatment of dry eye syndrome

Novagali Pharma has announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase III clinical trial of its Cyclosporine A ocular product, Nova22007, has been granted by the U.S. Food and Drug Administration (FDA).

27 Apr 2007

Increasing survival of organ transplant patients by reducing time interval for transported organs

Preservation of an organ intended for transplant during transport from donor to recipient is of primary concern in ensuring a successful transplant.

27 Apr 2007

New fetal heart monitor

New technology, the size of a mobile phone, which could save the life of an unborn child, has been developed by scientists from The University of Nottingham.

27 Apr 2007

New hope for diabetic retinopathy sufferers

Research increasingly shows promise to both slow and relieve the effects diabetic retinopathy, the most common complication of diabetes.

26 Apr 2007

Naproxen and celecoxib do not prevent Alzheimer's disease

Over-the-counter pain medication naproxen and prescription pain reliever celecoxib do not prevent Alzheimer's disease, according to a study published April 25, 2007, in the online edition of Neurology, the scientific journal of the American Academy of Neurology.

26 Apr 2007

New data supports safety of ranolazine but not its effectiveness

The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA .

25 Apr 2007

Neuromed licenses chronic pain product from ALZA Corporation

Neuromed Pharmaceuticals has announced that it has licensed from ALZA Corporation the exclusive U.S. rights to develop and commercialize OROS(R) Hydromorphone, an extended release formulation of a potent opioid analgesic in Phase 3 clinical development.

25 Apr 2007

Succimer therapy improves balance and movement in lead-exposed children

University of Cincinnati (UC) environmental health researchers say a therapy commonly used to remove dangerously high levels of lead from the body may also improve muscle functions associated with postural balance and movement in lead-exposed children.

25 Apr 2007

Variations of two common genes associated with progression to more advanced forms of age-related macular degeneration

Age-related macular degeneration (AMD; when the center of the inner lining of the eye suffers thinning, atrophy, and in some cases bleeding), which can lead to visual impairment and legal blindness, is associated with variations in the genes CFH and LOC387715.

25 Apr 2007

Ranolazine safe but not effective in reducing major cardiac events in ACS patients

25 Apr 2007

Professor Marc Feldmann wins top lifetime achievement award

The academic who developed a treatment for autoimmune diseases that has helped millions of patients around the world last night received a prestigious lifetime achievement award at this year's European Inventor of the Year awards.

24 Apr 2007